Page 25 - HME Business, May 2017

By David Kopf
A Simple Fix to a Complex Problem
Diabetes management company GlucoMe is using an everyday device to wrangle the pandemic-sized problem of diabetes care management.
The best tool for managing a patients’ health might already be sitting in their pocket. Such is the case for Israel-based GlucoMe, a company that is trying to revolutionize diabetes care management through smartphones.
Diabetic patients have been one group of patients that has been very familiar with managing their conditions and treatments, but they have not had access to the sorts of managed, connected care tools seen in some other care settings, such as sleep. GlucoMe is trying to change that by using, of all things, patients’ smart phones. Founded four years ago by CEO Yiftah Ben Aharon and board member Dov Moran — a person best known for being the inventor of the USB flash drive — GlucoMe approached the problem of managing an ubiquitous condition such as diabetes by seeking out a tool that is equally ubiquitous.
“When you take a look at diabetes worldwide, it’s pandemic,” Ben Aharon explains. “And the number of patients is constantly increasing, but the numbers of doctors, healthcare providers, nurses, kind of stays the same. So it just doesn’t make any sense to stick to the current treatment model, which says that the patients need to come to see the physician every three months.”
In fact, that care model is getting unsustainable. Having patients meeting with a specialist on a repeat basis creates unnecessary cost and prevents those specialists from focusing on the patients who most need help, or empowering self-sufficient patients to do an even better job managing their treatment. Change is needed.
A Three-Part Solution
So, Glucome came up with a three-part solution: tools for monitoring blood glucose and insulin levels; a cloud-based management platform; and the everyday smart phont to tie it all together.
The first part involves a highly simplified, yet accurate blood glucose monitor and a wireless monitor that turns any leading insulin pen into an automatic intake monitor. Both these devices connect with the users iOS or Android device using a very unique approach: sound.
“We don’t use Bluetooth, we don’t use Wifi, we don’t use cellular connectivity,” Ben Aharon says. “The hardware sensors connect with audio connectivity; it’s a special protocol that we developed. So basically the devices, they send a signal
over the air, just like the Shazam app, you might say. They are kind of ‘beeping’ the result, and in less than a second we can send the data to the smartphone. We utilize the microphone of the smartphone in order to pick up the signal and then we apply all kinds of signal processing in order to make sure that we have the right signal.”
Ben Aharon notes that GlucoMe has tested the unique audio connectivity approach in 1,260 scenarios at various noise levels and diverse environments, such as office settings, concerts, restaurants, planes, trains and even the Great Outdoors, and it has performed with 100 percent accuracy with no loss. It can work up to 10 feet and 90 dB noise levels. Moreover, the goal is to make this connectivity open.
“Obviously we don’t intend to develop all the sensors around the world,” Ben Aharon says. ”So we can pick up and integrate data from all kinds of data sources including other blood glucose meter pumps, continuous glucose monitors, etc. to make sure that we have the right data in order to take the right decision.”
The next part is GlucoMe’s mobile app, which has two purposes: to transmit patient data into GlucoMe’s cloud-based system to help physicians manage their
Management Solutions | Technology | Products
GlucoMe leverages iOS and Android phones to easily and simply get diabetes data from patients’ glucose monitors and insulin pens, and into a cloud- based management system.
patients, and to provide patients with feedback and management tools so that they can help track and manage their conditions, as well.
“Basically the patients are walking with the sensors and with the mobile applica- tions,” Ben Aharon says. “And once the data goes to the Cloud, then the magic begins. Once you have data you can start working with it.
That’s where the third part, the cloud-based care management system, comes into play. With that physicians have much more granular, and real-time feedback on how patients are doing indivdually, and on an overall basis.
“We aggregate the data and we provide the healthcare provider, it could be like the nurse, the GP, the PCP, the endocrinologist, we provide them first of all raw data, which is a lot of data,” Ben Aharon explains. “We wouldn’t like them to waste their time analyzing this data manually, so we provide all kinds of analytics which kind of point them to the right direction, making sure that they know exactly what needs to be done, what needs to be known about this specific patient.
“And the most interesting part in our cloud-based system is that we actually provide treatment recommendation,” he continues. “We have a decision support system which analyzes the data, crunches the number, and provides the physician information such as which medication should be used by this specific patient, what should be the dosage, when should the patient take the medication. We constantly analyze the data to provide the best treatment plan for this specific patient.”
While the system might make recommendations, it still provides the physician a total level of control. Doctors review the information to make the right decisions.
“The physician can drill down and see what was the reason for taking that deci- sion,” Ben Aharon says. “We place the physician as the gatekeeper. The system makes recommendation, but decision making goes only to the healthcare provider.”
In terms of availability, GlucoMe has a presence in Europe, Israel, Africa and India. Where the United States is concerned, the company is conducting clinical trials at the Rainier Clinic in Seattle, Wash., and Ben Aharon says that the company intends to conduct additional trials in 2017, having just finalized the protocol for a trial at John Hopkins that it plans to run during this year.
The company will continue trailing the system and working on FDA approval during 2017 with the expectation of completing the FDA process by end of year so that the system will be available in the U.S. market in early 2018, according to Ben Aharon. Bearing that in mind, the company just named a North American execu- tive vice president and general manager (see “People in HME,” on page 13).
GlucoMe Diabetes Management
GlucoMe
(800) 446-3908
www.glucome.com
Product Profile
hme-business.com | May 2017 | HMEBusiness 25